NSE: ZYDUSLIFE · 4 November 2026
- Zydus Lifesciences Ltd (ZYDUSLIFE) shares declined sharply by 4.23% today, closing at ₹1,188.10 after opening at ₹1,251.70. The stock traded within a wide intraday range, hitting a high of ₹1,266.60 and a low of ₹1,182.40.
- Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of ₹79,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at ₹18,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to ₹9,255 million. The company reported R&D investments of ₹6,573 million, accounting for 8.3% of revenues, and organic capex of ₹4,655 million.
- Trading volume was 3.58 times the 20-day average daily volume.
Why is Zydus Lifesciences share price falling on 4 November 2026?
Zydus Lifesciences Ltd (ZYDUSLIFE) shares declined sharply by 4.23% today, closing at ₹1,188.10 after opening at ₹1,251.70. The stock traded within a wide intraday range, hitting a high of ₹1,266.60 and a low of ₹1,182.40.
The broader market and sector moved in the opposite direction, providing an interesting contrast to the stock's performance. The benchmark Nifty rose by 0.63%, while the thematic sector index Nifty Pharma advanced by 0.42%. Zydus Lifesciences underperformed both the broader market and its sector peers significantly during the session.
The move coincided with the release of the company's financial results for the quarter ended September 30, 2026, alongside reports of USFDA inspection observations at its Moraiya and Ahmedabad facilities. While the company reported a 29% year-on-year increase in revenue from operations to ₹79,096 million, net profit for the quarter declined 27% year-on-year to ₹9,255 million, and EBITDA dropped 6% to ₹18,945 million.
49.43 lakh shares traded by 4 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 13.80 lakh shares (3.58 times). The five-day average daily volume was 16.14 lakh shares. Separately, the NSE report for 4 November 2026 showed 17.98 lakh shares delivered, representing 36.38% of that day’s traded volume. The same report recorded 173,344 trades.
The stock declined 4.23% alongside heavy trading volume after reporting a year-on-year drop in quarterly net profit and EBITDA despite higher revenues, alongside disclosed USFDA inspection observations at key manufacturing plants.
Latest Company Developments
Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of ₹79,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at ₹18,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to ₹9,255 million. The company reported R&D investments of ₹6,573 million, accounting for 8.3% of revenues, and organic capex of ₹4,655 million.
Quarterly earnings figures and margin contraction provide critical visibility into the company's operational profitability and growth trajectory.
The company disclosed that USFDA inspections at its SEZ II facility in Ahmedabad and formulations plant in Moraiya concluded with one and five observations, respectively. Zydus stated that it is working closely with the regulator to address these observations expeditiously. Following the inspection at Moraiya, the company also received approval for a transdermal patch product on October 21, 2026.
Regulatory observations at key manufacturing sites can influence compliance sentiment and future product approval timelines in regulated markets.
Upon completion of conditions precedent and closing adjustments under the Business Transfer Agreement dated September 17, 2024, Zydus Lifesciences completed the acquisition of the API business of Sterling Biotech Limited on November 2, 2026. The integration aims to strengthen the company's backward integration and manufacturing capabilities. This follows ongoing strategic alignment across its domestic and international manufacturing footprint.
Expanding API operations enhances backward integration and supply chain control across the pharmaceutical portfolio.
Outcome of Board Meeting held on November 04, 2026.
Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 6.88% on 30 September 2026. This compares with 5.12% on 30 June 2026, a change of +1.76 percentage points.
The filing reported 41 MF/UTI holders.
Research & Brokerage Views
Included Zydus Lifesciences among stock recommendations in its daily notes.
Maintained an Outperform rating following business updates.
Raised target price while maintaining a Sell rating on valuation concerns.
Maintained a Neutral rating citing limited immediate upside potential.
What to Watch Next
- Company management commentary and answers during the post-results earnings call
- Regulatory response and resolution progress regarding USFDA observations at Moraiya and Ahmedabad facilities
- Execution and integration progress following the acquisition of Sterling Biotech's API business
- Sustained performance of domestic branded formulations and US specialty product momentum
Other Dated Coverage
- Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.84% | 23 October 2026 — 23 October 2026
- Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Rising 1.58% | 22 October 2026 — 22 October 2026
- Zydus Lifesciences in Focus After Sri Lanka Plant Agreement; What to Watch | 16 October 2026 — 16 October 2026
More Zydus Lifesciences news and dated analysis →
Frequently Asked Questions
What is the latest Zydus Lifesciences company news?
Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of ₹79,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at ₹18,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to ₹9,255 million. The company reported R&D investments of ₹6,573 million, accounting for 8.3% of revenues, and organic capex of ₹4,655 million.
How strong was Zydus Lifesciences’s trading volume?
49.43 lakh shares traded, 3.58 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.